Editas Medicine Inc (EDIT) stock saw a modest uptick, ending the day at $1.41 which represents a slight increase of $0.07 or 5.22% from the prior close of $1.34. The stock opened at $1.37 and touched ...
A look at Intellia Therapeutics, Inc. and Editas Medicine, Inc., including their restructuring and pipeline prioritization.
Equities research analysts at Leerink Partnrs decreased their FY2025 earnings per share (EPS) estimates for Editas Medicine in a note issued to investors on Wednesday, January 22nd. Leerink Partnrs ...
In this article, we are going to take a look at where Editas Medicine, Inc. (NASDAQ:EDIT) stands against the other CRISPR stocks. The pharmaceutical industry is buzzing with innovation ...
Analysts at Zacks Research decreased their FY2024 earnings per share (EPS) estimates for Editas Medicine in a report issued on Tuesday, January 21st. Zacks Research analyst A. Chakraborty now expects ...
Editas Medicine (EDIT – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Yanan Zhu ...
Editas Medicine ( (EDIT) ) has provided an announcement. Editas Medicine announced new in vivo preclinical proof of concept data and outlined its strategic priorities and key milestones for 2025, ...
TD Cowen analyst Phil Nadeau maintained a Buy rating on Editas Medicine (EDIT – Research Report) today. The company’s shares closed yesterday ...
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.
CRISPR stock decline is influenced by Editas Medicine's struggles, but CRSP remains strong with FDA approval and strategic ...
Editas Medicine Inc (EDIT) stock saw a modest uptick, ending the day at $1.22 which represents a slight increase of $0.08 or 7.02% from the prior close of $1.14. The stock opened at $1.2 and touched a ...